Why the study?
Delayed presentations of peripartum cardiomyopathy can occur, leading to significant diagnostic challenges and complicating treatment.
Does guideline-directed medical therapy for HFrEF improve symptoms and LVEF in a patient with delayed-onset peripartum cardiomyopathy?
Case Report (n=1)
Does guideline-directed medical therapy for HFrEF improve symptoms and LVEF in a patient with delayed-onset peripartum cardiomyopathy?
Early initiation of guideline-directed medical therapy for HFrEF, including ARNI and SGLT2 inhibitors, can lead to full functional recovery in patients with delayed-onset peripartum cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Supports GDMT with ARNI/SGLT2i for LVEF recovery in peripartum cardiomyopathy; hypothesis-generating, needs prospective confirmation.
Background: Peripartum cardiomyopathy (PPCM) is a rare but potentially fatal cause of heart failure that occurs towards the end of pregnancy or within the first 5 months postpartum, in the absence of other identifiable cause of cardiac dysfunction. It is characterized by left ventricular systolic impairment, with an ejection fraction (LVEF) typically ≤ 45%. While most cases are diagnosed shortly after delivery, delayed presentations can occur, leading to significant diagnostic challenges and complicate treatment. Case summary: We report a case of a 40-year-old multiparous (Para 3) woman, who developed progressive dyspnoea beginning 2 months after delivery. Despite two earlier medical care visits, her symptoms were initially misdiagnosed. She represented with overt symptoms of heart failure 1 month later. Investigations encompassing transthoracic echocardiography, cardiac magnetic resonance imaging, coronary angiography, and NT-proBNP confirmed PPCM with a severely reduced LVEF of 16%. She was promptly initiated on guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF), including an angiotensin receptor-neprilysin inhibitor and a sodium-glucose cotransporter-2 inhibitor. At 3-month follow-up, her symptoms had resolved, and LVEF recovered to 56%. Discussion: This case highlights the diagnostic challenge of delayed-onset PPCM and reinforces the importance of maintaining high suspicion in postpartum women presenting with persistent dyspnoea. Early initiation of GDMT for HFrEF can lead to full functional recovery. Routine postpartum surveillance should include careful assessment for cardiopulmonary symptoms, even in the absence of overt risk factors, to prevent delays in diagnosis and management.
No takes yet. Share an insight, caveat, or question.
Asri et al. (2025) conducted a case report in Peripartum cardiomyopathy (PPCM) (n=1). Guideline-directed medical therapy (sacubitril/valsartan, empagliflozin, bisoprolol, spironolactone) was evaluated on Left ventricular ejection fraction (LVEF) at 3 months.
Synapse has enriched 10 related papers. Consider them for comparative context: